Science image (IMAGE)

Salk Institute

Science image

Caption

Stites challenged the prevailing idea that all cancer-associated KRAS gene mutations caused resistance to the available and effective anti-cancer drug cetuximab. His team was able to find and classify 10 drug-sensitive KRAS mutations (green). Also shown are some the drug-resistant mutations (red). Clinical trials could help match colorectal cancer patients with better treatment options, such as cetuximab, if they have drug-sensitive KRAS mutations.

Credit

Cell Reports and the Salk Institute

Usage Restrictions

with credit and related coverage.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.